EIP Pharma Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 7
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $5.08M
Latest Deal Amount
  • Investors
  • 5

EIP Pharma General Information

Description

Developer of central nervous system focused drugs designed to offer treatment for Alzheimer's disease. The company's drug promotes recovery of function in patients suffering from acute neurologic injury, enabling doctors to treat brain diseases of Alzheimer's and other central nervous system drugs effectively and improve episodic memory functions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 120 Street James Avenue
  • Suite 6017
  • Boston, MA 02116
  • United States
+1 (617) 000-0000

EIP Pharma Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

EIP Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 15-Jan-2021 $5.08M 000.00 Completed Generating Revenue
6. Later Stage VC 23-Jan-2020 00.000 000.00 Completed Generating Revenue
5. Later Stage VC 15-Apr-2019 000.00 000.00 Completed Generating Revenue
4. Early Stage VC (Series B) 02-Apr-2018 000.00 000.00 0000 Completed Generating Revenue
3. Angel (individual) 06-Jan-2017 00000 00.00 Completed Generating Revenue
2. Angel (individual) 01-Jan-2017 $4.2M $5.7M Completed Generating Revenue
1. Early Stage VC (Series A1) 01-Oct-2016 $1.5M $1.5M Completed Generating Revenue
To view EIP Pharma’s complete valuation and funding history, request access »

EIP Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A2 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A1 17,033,883 $0.001000 $0.09 $0.09 1x $0.09 48.55%
To view EIP Pharma’s complete cap table history, request access »

EIP Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of central nervous system focused drugs designed to offer treatment for Alzheimer's disease. The company's dru
Drug Discovery
Boston, MA
7 As of 2021
000.00
0000000000 0 000.00

00000000

lla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mol
0000 000000000
Clarksville, MD
0 As of 0000
00.000
000000 0

0000000

lamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in vol
0000 000000000
Newton, MA
0 As of 0000
0000
0000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EIP Pharma Competitors (23)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NeuroNascent Venture Capital-Backed Clarksville, MD 0 00.000 000000 0
0000000 0000000000 Venture Capital-Backed Newton, MA 0 0000 0000000000 0000
000000000 00000000 Venture Capital-Backed New York, NY 00 000.00 00000000 000.00
00000000 000000000 Formerly VC-backed Boston, MA 00 00000 000000000 00000
0000000 Venture Capital-Backed Framingham, MA 00 000.00 0000000000 0 000.00
You’re viewing 5 of 23 competitors. Get the full list »

EIP Pharma Patents

EIP Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210077497-A1 Compositions and methods for treating dementia with lewy bodies Pending 12-Jul-2019 0000000000
US-10653695-B2 Pharmaceutical formulations of neflamapimod Active 12-Mar-2018 0000000000
US-20190275045-A1 Pharmaceutical formulations of neflamapimod Granted 12-Mar-2018 0000000000
US-20200308176-A1 Co-crystals of neflamapimod (vx-745) Pending 18-Sep-2017 0000000000
US-10420770-B2 Compositions and methods for treating dementia Active 21-Apr-2016 A61K31/519

EIP Pharma Executive Team (4)

Name Title Board Seat Contact Info
John Alam MD Co-Founder, President, Chief Executive Officer & Board Member
Noel Donnelly Chief Financial Officer
Sylvie Gregoire Co-Founder & Executive Chairperson
You’re viewing 3 of 4 executive team members. Get the full list »

EIP Pharma Board Members (5)

Name Representing Role Since
Frank Zavrl Self Board Member 000 0000
Jeffrey Poulton Self Board Member 000 0000
John Alam MD EIP Pharma Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Sylvie Gregoire Self Co-Founder & Executive Chairperson 000 0000
Tatjana May Self Board Member 000 0000
To view EIP Pharma’s complete board members history, request access »

EIP Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EIP Pharma Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Adage Capital Management Hedge Fund Minority 000 0000 000000 0
Mossrock Capital Other Minority 000 0000 000000 0
Rock Springs Capital Hedge Fund Minority 000 0000 000000 0
Access Industries Corporation Minority 000 0000 000000 0
Founders Fund Venture Capital Minority 000 0000 000000 0
To view EIP Pharma’s complete investors history, request access »